


Product Name : CFI-400945 fumarate
Cat. No. : PC-63238
CAS No. : 1616420-30-4
Molecular Formula : C₃₇H₃₈N₄O₇
Molecular Weight : 650.732
Target : Polo-like Kinase (PLK)
Solubility : DMSO: ≥ 166.66 mg/mL



Biological Activity

CFI-400945 (Ocifisertib) fumarate is a potent, highly selective, orally available **PLK4** inhibitor with K_i of 0.26 nM and IC_{50} of 2.8 nM, does not significantly inhibit PLK1/2/3 at 50 μ M.

CFI-400945 causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI_{50} =5 nM, OVCAR-3 GI_{50} =18 nM).

CFI-400945 significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.

References

Sampson PB, et al. *J Med Chem.* 2015 Jan 8;58(1):147-69.

Mason JM, et al. *Cancer Cell.* 2014 Aug 11;26(2):163-76.

Lohse I, et al. *Oncotarget.* 2017 Jan 10;8(2):3064-3071.

Kawakami M, et al. *Proc Natl Acad Sci U S A.* 2018 Feb 20;115(8):1913-1918.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com